New Data Presented at AD/PD™ 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease

The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regionsPhase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau... | March 29, 2023

Related Keywords

Sweden ,Gothenburg ,Vastra Gotalands Lan ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Priya Singhal ,Jack Cox ,Mike Hencke ,Youtube ,Exchange Commission ,Nasdaq ,Facebook ,Biogen Inc ,Linkedin ,Twitter ,Alzheimer Association ,International Conference On Alzheimer ,Head Of Development At Biogen ,International Conference ,Executive Vice President ,Safe Harbor ,Tau Protein ,Accessed March ,Tau Topic ,Accessed February ,Biogen Inc Stock Exchange ,News ,Information ,Press Release ,The ,Iib080 ,Hase ,Tb ,Linical ,Study ,Us ,First ,O ,Show ,Reduction ,F ,This ,Magnitude ,N ,Au ,Pet ,Cross ,Rain ,Egionsphase ,Howed ,End ,Sustained ,F Biib Us09062x1037 ,